RAPT Therapeutics Inc. (RAPT) - Long-Term Debt to Capital Coefficient

RAPT Therapeutics, Inc. (RAPT) develops selective molecules for the targeted treatment of allergic inflammation without compromising overall immunity. The price characteristic (separate_debt_long_eq) is recorded at 0.00, while the biotech's success relies on the safety of its candidates and patent purity. The company's prospects are limited by a lack of commercialized products and stringent regulatory oversight of clinical trials in laboratories.

Investors utilize this ratio to assess financial stability and the extent of the company's reliance on external borrowings over a long-term horizon. The long-term debt-to-equity ratio on this long-term debt load chart demonstrates the underfunding risk of RAPT Therapeutics, Inc. (RAPT), whose operations are limited to the clinical trial stage and are critically dependent on regulatory decisions.